Active Not Recruiting PHASE1 NCT07038369

A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations

A Phase 1 Study of a Selective AKT1 E17K Allosteric Inhibitor, ATV-1601, in Patients With Advanced Solid Tumors

Sponsor: Atavistik Bio, Inc

Interventions ATV-1601 ATV-1601 + Fulvestrant

Updated 7 times since 2025 Last updated: Feb 20, 2026 Started: Jul 29, 2025 Primary completion: Aug 31, 2028 Completion: Jan 31, 2029

This PHASE1 trial investigates Advanced Solid Tumors and Breast Cancer and is currently ongoing. Atavistik Bio, Inc leads this study, which shows 7 recorded versions since 2025 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

7 versions recorded

Feb 2026 — Present [monthly]

Active Not Recruiting PHASE1

Status: Recruiting → Active Not Recruiting
Jan 2026 — Feb 2026 [monthly]

Recruiting PHASE1
Dec 2025 — Jan 2026 [monthly]

Recruiting PHASE1
Nov 2025 — Dec 2025 [monthly]

Recruiting PHASE1
Oct 2025 — Nov 2025 [monthly]

Recruiting PHASE1

▶ Show 2 earlier versions

Sep 2025 — Oct 2025 [monthly]

Recruiting PHASE1

Status: Not Yet Recruiting → Recruiting
Jul 2025 — Sep 2025 [monthly]

Not Yet Recruiting PHASE1

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Atavistik Bio, Inc

Data source: Atavistik Bio, Inc

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Barcelona, Spain , Boston, United States , Cleveland, United States , Columbus, United States , Houston, United States , Lake Mary, United States , Los Angeles, United States , Lyon, France , Madrid, Spain , Portland, United States and 2 more locations